Cited by

• Development of Therapeutics That Induce Mitochondrial Biogenesis for the Treatment of Acute and Chronic Degenerative Diseases.

  Cameron RB, Beeson CC, Schnellmann RG. Cameron RB, et al. J Med Chem. 2016 Dec 8;59(23):10411-10434. doi: 10.1021/acs.jmedchem.6b00669. Epub 2016 Sep 27. J Med Chem. 2016. PMID: 27560192 Free PMC article. Review.
• Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP.

  Puurunen J, Lücke C, Schwabe U. Puurunen J, et al. Naunyn Schmiedebergs Arch Pharmacol. 1978 Aug;304(1):69-75. doi: 10.1007/BF00501379. Naunyn Schmiedebergs Arch Pharmacol. 1978. PMID: 211449 No abstract available.
• Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca(2+) responses in endothelial cells.

  Campos-Toimil M, Keravis T, Orallo F, Takeda K, Lugnier C. Campos-Toimil M, et al. Br J Pharmacol. 2008 May;154(1):82-92. doi: 10.1038/bjp.2008.56. Epub 2008 Mar 3. Br J Pharmacol. 2008. PMID: 18311187 Free PMC article.
• Characteristic behavioural alterations in rats induced by rolipram and other selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitors.

  Wachtel H. Wachtel H. Psychopharmacology (Berl). 1982;77(4):309-16. doi: 10.1007/BF00432761. Psychopharmacology (Berl). 1982. PMID: 6182575
• NSD 1034: an amino acid decarboxylase inhibitor with a stimulatory action on dopamine synthesis not mediated by classical dopamine receptors.

  Nissbrandt H, Engberg G, Wikström H, Magnusson T, Carlsson A. Nissbrandt H, et al. Naunyn Schmiedebergs Arch Pharmacol. 1988 Aug;338(2):148-61. doi: 10.1007/BF00174863. Naunyn Schmiedebergs Arch Pharmacol. 1988. PMID: 3141816